Skip to main content

25 October 2012

Smiths Medical, a division of global technology business Smiths Group, announces that its advanced safety connector for injecting epidural medication has received clearance from the U.S. Food and Drug Administration (FDA).

The Portex® CorrectInject™ Safety System, designed to reduce the risk of potentially fatal tube misconnections, is the first safety system of its kind to receive a 510(k) clearance from the FDA. This allows it to be marketed in the US.

Smiths Medical President Srini Seshadri said: “As a global leader in safety medical devices, we are delighted to have developed an innovative solution to a long-standing and serious medication delivery issue. FDA clearance is a crucial component in our plans to roll out CorrectInject™ in major markets.”

Misconnections can occur because epidural, intravenous, enteral and other infusion lines are similar.  However, the connectors of the CorrectInject™ system are uniquely tapered and threaded to be incompatible with standard intravenous Luer connectors. Its bright yellow components also clearly indicate a neuraxial (spinal and epidural) delivery route. This further reduces the chances of confusing vein-delivered and neuraxial-delivered medication, an error which can cause death or serious illness.

Related articles

Aerial Shot Of Forest

John Crane awarded key energy transition contracts in North America

Find out more Call to action arrow icon
Mobile Scanner

Advanced X-ray screening equipment used to help secure NFL Super Bowl

Find out more Call to action arrow icon
Japan Airport

Smiths Detection technology to be used at Fukuoka International Airport 

Find out more Call to action arrow icon